Kalorama: Pharmacyclics Acquisition Strengthens AbbVie Pipeline
NEW YORK, March 12, 2015 /PRNewswire/ -- AbbVie's recent acquisition of Pharmacyclics for $21 billion strengthens AbbVie's already comprehensive pipeline and increases the company's growth prospects, according to Kalorama Information. Kalorama's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies such as AbbVie. This report provides long-term company sales forecasts based on recent market conditions.
The healthcare market researcher's report can be found at KI: http://www.kaloramainformation.com/Pharmaceutical-Company-Pipeline-8102423/.
With the acquisition, AbbVie gains Pharmacyclics' flagship asset Imbruvica® (ibrutinib), a highly effective treatment for hematologic malignancies, accelerating AbbVie's presence in oncology. This strengthens AbbVie's already robust pipeline and establishes a leadership position in the hematological oncology market, which now approaches $24 billion globally.
The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. Kalorama's report surveys the key players in the market, including:
- Revenues
- Recent R&D Spending by Major Pharma
- Geographic Breakout of Revenues
- Performance of Specific Products
- Performance by Drug Category
- Late-Stage Pipeline
- Projections of Revenues to 2023
Beyond this acquisition, AbbVie will continue to focus on advanced technologies and innovative products to deliver medicines to patients around the globe. It is seeking to developing small molecule and biologics products in key areas like oncology, and even in rare diseases. The company is also driving growth through geographic expansion. In 2014, the company announced an investment in a new small molecule and biologics manufacturing facility in Singapore. The intended focus of this facility will be in emerging compounds for oncology and immunology. AbbVie uses both partnerships and internal manufacturing to make its products. There are 12 AbbVie manufacturing sites around the globe—these are found in the U.S. and Europe.
The companies covered in the report are:
- Pfizer, Inc.
- Novartis AG
- Roche Ltd.
- Merck & Co., Inc.
- Sanofi
- Glaxosmithkline PLC
- Johnson & Johnson
- Astra Zeneca plc
- Eli Lilly and Company
- Abbvie, Inc.
- Teva Pharmaceutical Industries, Ltd.
- Amgen, Inc.
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Co., LTD
- Bayer AG
- Novo Nordisk
- Boehringer Ingelheim GmbH
- Daiichi Sankyo
- Astellas
- Gilead Sciences
- Otsuka Pharmaceutical
- Merck KGAA
- Actavis
- Mylan
- Baxter International
For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical, including biopharmaceutical products. The market excludes consumer pharmaceuticals; diagnostics; devices; chemicals; agriculture; and animal health. Strategic acquisitions and partnerships with biotech companies have allowed traditional pharmaceutical companies an opportunity to become diverse in pipelines and product offerings. Companies like Amgen, which specialize in biotechnology, now compete with a growing number of what the industry has once considered to be the traditional pharmaceutical company, This is a trend that is expected to continue as small biotechnology-focused companies are acquired by companies in the industry such as Pfizer, Novartis, and Roche.
Information on Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 can be found at KI: http://www.kaloramainformation.com/Pharmaceutical-Company-Pipeline-8102423/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Share this article